Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters
In research settings, visualization of tumors or tumor cells is often done using either bioluminescence or fluorescence. However, both of these methods have shortcomings: bioluminescence is not sensitive enough to sort individual tumor cells, and fluorescence cannot be used effectively to view internal tumors and is best used with surface tumors.
48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio
CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner.
Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders
Summary:
The National Institute on Drug Abuse's Medications Discovery Research Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 4-phenylpiperazine derivatives as dopamine D3 selective ligands.
Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use
This technology includes an innovative method for differentiating astrocytes from neural stem cells (NSCs). The process involves using Life Technologies StemPro embryonic stem cell serum-free medium to initially guide NSCs towards a neuronal lineage. Over a period of 28-35 days, as the cells are continually passaged, neurons gradually die off, leading to the proliferation of astrocytes. By the end of this differentiation protocol, approximately 70% of the cells exhibit markers characteristic of mature astrocytes, specifically GFAP.
MC38 B2m KO Cell Line
Summary:
The National Cancer Institute (NCI) seeks licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line that models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation. This research tool provides an opportunity to study checkpoint-refractory tumors and evaluate alternative or combination immunotherapy strategies for cancers that evade conventional T-cell–mediated recognition.
Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology
Summary:
The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.
Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
Summary:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291 and https://www.jax.org/strain/036290.
T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies
Summary:
The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma.
Establishment and characterization of the A 1847 human ovarian carcinoma line
Summary:
The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.